For patients with breast cancer and bone metastases, denosumab delayed skeletal-related side effects five months longer compared to those on zoledronic acid, according to results presented at the 33rd Annual CTRC-AACR San ...

Medicine & Health - Cancer

Dec 10, 2010 not rated yet 0

Twice-yearly treatment with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer. The report from an ...

Medicine & Health - Cancer

Aug 11, 2009 not rated yet 0